Related News
Sanofi picks Shanghai for R&D center
Print Edition
FRENCH pharmaceutical giant Sanofi opened a research hub in Shanghai yesterday, the company said, as foreign drug firms face government scrutiny after GlaxoSmithKline was found guilty of bribery last week.
The facility, the fifth global hub for the company and its first in Asia, groups 12 countries including China, Sanofi said.
The operation will employ 1,400 people, it said. Sanofi officials declined to give an investment figure.
“With the launch of the hub, we will continue to pioneer R&D (research and development) in Asia-Pacific,” said Frank Jiang, Sanofi’s head of R&D in Asia-Pacific.
Shanghai has sought to attract multinational companies to set up regional headquarters in the city with the number reaching 470 as of mid-year, according to state media.
The Shanghai facility will research and develop products in four broad areas — biopharmaceuticals, vaccinations, disease and animal health — in cooperation with other global hubs, company officials said.
Sanofi already has existing R&D capabilities in China, along with seven plants producing mainly for the China market, they said.
The opening comes just days after China fined UK drugmaker GSK 3 billion yuan (US$489 million) for bribery and gave jail terms of up to four years to five executives.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
